Photocure ASA posts modest revenue growth and flat adjusted EBITDA in Q2 2026
Executive summary: Photocure ASA reported Q2 2026 Hexvix/Cysview revenues of NOK 140.0 million and adjusted EBITDA of NOK 27.2 million. The slight year‑over‑year revenue increase with stable profitability shows consistent demand for its oncology imaging product and steady cost management.
Who is involved: Photocure ASA (OSE: PHO), its shareholders, and the Nordic urology‑care market.
Likely next: The company will publish its half‑year and full‑year guidance later in 2026, with the next quarterly update expected around October 2026.
Photocure ASA’s second‑quarter 2026 release shows Hexvix/Cysview revenues rising to NOK 140.0 million from NOK 135.6 million a year earlier, while adjusted EBITDA remained essentially unchanged at NOK 27.2 million versus NOK 27.0 million. The figures indicate steady demand for the company’s urology imaging agent with no major shift in profitability. Overall, the result reads as a neutral update that sustains the current run‑rate without signaling acceleration or deterioration.
Timeline
- — Photocure ASA: Results for the second quarter of 2026 (PR Newswire)
Analysis — what this means
Sectors affected
- Urology imaging agents
- Photodynamic diagnostics
Historical parallels
- Photocure Q2 2025 results: revenue NOK 135.6 million, adjusted EBITDA NOK 27.0 million (July 2025)
Key entities
Sources
- Photocure ASA: Results for the second quarter of 2026 — PR Newswire